Skip to main content
Premium Trial:

Request an Annual Quote

Seegene Q2 Revenues up 11 Percent

NEW YORK — South Korean diagnostics company Seegene on Wednesday reported a nearly 11 percent year-over-year increase in its second quarter revenues amid higher sales of its infectious disease testing reagents and PCR equipment in Europe and North America.

For the three-month period ended June 30, Seegene's revenues climbed to ₩303.7 billion ($259.6 million) from ₩274.8 billion a year earlier. European sales in Q2 grew 36 percent to ₩148.1 billion from ₩109.2 billion, while sales in North America were up 68 percent in the second quarter to ₩42.6 billion from ₩25.3 billion.

Total reagents sales in Q2 2021 were ₩246.6 billion, up from ₩232.1 billion a year ago, while equipment sales grew to ₩57.1 billion in the recently completed quarter compared to ₩42.7 billion a year ago.

Seegene's net income for the quarter was ₩116.7 billion versus ₩165.3 billion in the year-ago quarter.

Second quarter R&D spending surged 230 percent to ₩18.5 billion from ₩5.6 billion, while SG&A costs more than doubled to ₩78.0 billion from ₩32.0 billion a year earlier.

At the end of June, Seegene had cash and cash equivalents totaling ₩264.0 billion.

"Although the pandemic is still somewhat unpredictable, it is extremely crucial to conduct surveillance screenings as the virus continues to mutate," Myungkun Kim, Seegene's managing director of investor relations, said in a statement. "Our multiplex reagents are capable of detecting major COVID-19 variants in a single test while they are price competitive, as well."

"Also, as we are expanding our market in unexplored regions such as Asian and Latin American countries, we will be able to generate more valuable results in the global arena," he added.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.